within Pharmacolibrary.Drugs.ATC.C;

model C09DB06
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.32,
    Cl             = 0.0005666666666666667,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.034,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600,            
    Vdp             = 0.06,
    k12             = 37,
    k21             = 37
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C09DB06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Losartan and amlodipine is a fixed-dose combination drug used for the treatment of hypertension. Losartan is an angiotensin II receptor blocker (ARB) that relaxes blood vessels, while amlodipine is a calcium channel blocker that also dilates blood vessels. This combination is approved and commonly used today for patients whose blood pressure is not adequately controlled by either drug alone.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for losartan and amlodipine fixed-dose combination in healthy adults. No dedicated population pharmacokinetic studies for the combination product were found; parameters are approximated based on published data for individual drugs.</p><h4>References</h4><ol><li><p>Jeon, I, et al., &amp; Chung, JY (2022). Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan and Chlorthalidone Compared to Concurrent Administration of the Separate Components. <i>Clinical pharmacology in drug development</i> 11(1) 91–99. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.963&quot;>10.1002/cpdd.963</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34159751/&quot;>https://pubmed.ncbi.nlm.nih.gov/34159751</a></p></li><li><p>Choi, Y, et al., &amp; Yu, KS (2016). Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study. <i>Drug design, development and therapy</i> 10 3021–3028. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S113891&quot;>10.2147/DDDT.S113891</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27703330/&quot;>https://pubmed.ncbi.nlm.nih.gov/27703330</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C09DB06;
